


Inventors: Huse and Wu
Serial No.: 09/339,922
Filed: June 24, 1999



APPENDIX A

In the specification:

On page 1, please delete the title on lines 1-2 and substitute therefor:

ANTI- $\alpha_v\beta_3$ RECOMBINANT HUMAN ANTIBODIES AND NUCLEIC ACIDS
ENCODING SAME

In the Claims:

1. (Amended) An enhanced LM609 grafted antibody exhibiting selective binding affinity to $\alpha_v\beta_3$, or a functional fragment thereof, comprising a CDR selected from the group consisting of a V_H CDR2 referenced as SEQ ID NO:104; a V_H CDR3 referenced as SEQ ID NO:106; and a V_L CDR1 referenced as SEQ ID NO:110, said grafted antibody or functional fragment thereof having integrin $\alpha_v\beta_3$ binding activity, integrin $\alpha_v\beta_3$ binding specificity or integrin $\alpha_v\beta_3$ -inhibitory activity, wherein LM609 refers to the murine antibody having the heavy chain variable region amino acid sequence referenced as SEQ ID NO:6 and the light chain variable region amino acid sequence referenced as SEQ ID NO:8.

3. (Amended) An enhanced LM609 grafted antibody having substantially the same sequence as [the] an enhanced LM609 grafted antibody [of claim 1], or a functional fragment thereof,

Inventors: Huse and Wu
Serial No.: 09/339,922
Filed: June 24, 1999

said grafted antibody comprising a CDR selected from the group consisting of a V_H CDR2 referenced as SEQ ID NO:104; a V_H CDR3 referenced as SEQ ID NO:106; and a V_L CDR1 referenced as SEQ ID NO:110, said grafted antibody or functional fragment thereof having integrin $\alpha_v\beta_3$ binding activity, integrin $\alpha_v\beta_3$ binding specificity or integrin $\alpha_v\beta_3$ -inhibitory activity, wherein LM609 refers to the murine antibody having the heavy chain variable region amino acid sequence referenced as SEQ ID NO:6 and the light chain variable region amino acid sequence referenced as SEQ ID NO:8.

4. (Amended) An enhanced LM609 grafted antibody exhibiting selective binding affinity to $\alpha_v\beta_3$, or a functional fragment thereof, comprising the V_H CDR1 referenced as SEQ ID NO:34; the V_H CDR2 referenced as SEQ ID NO:102; the V_H CDR3 referenced as SEQ ID NO:106; the V_L CDR1 referenced as SEQ ID NO:108; the V_L CDR2 referenced as SEQ ID NO:112; and the V_L CDR3 referenced as SEQ ID NO:90, said grafted antibody or functional fragment thereof having integrin $\alpha_v\beta_3$ binding activity, integrin $\alpha_v\beta_3$ binding specificity or integrin $\alpha_v\beta_3$ -inhibitory activity, wherein LM609 refers to the murine antibody having the heavy chain variable region amino acid sequence referenced as SEQ ID NO:6 and the light chain variable region amino acid sequence referenced as SEQ ID NO:8.

6. (Amended) An enhanced LM609 grafted antibody having substantially the same sequence as [the] an enhanced LM609 grafted antibody [of claim 4], or a functional fragment thereof,

Inventors: Huse and Wu
Serial No.: 09/339,922
Filed: June 24, 1999

comprising the V_H CDR1 referenced as SEQ ID NO:34; the V_H CDR2 referenced as SEQ ID NO:102; the V_H CDR3 referenced as SEQ ID NO:106; the V_L CDR1 referenced as SEQ ID NO:108; the V_L CDR2 referenced as SEQ ID NO:112; and the V_L CDR3 referenced as SEQ ID NO:90, said grafted antibody or functional fragment thereof having integrin $\alpha_v\beta_3$ binding activity, integrin $\alpha_v\beta_3$ binding specificity or integrin $\alpha_v\beta_3$ -inhibitory activity, wherein LM609 refers to the murine antibody having the heavy chain variable region amino acid sequence referenced as SEQ ID NO:6 and the light chain variable region amino acid sequence referenced as SEQ ID NO:8.

7. (Amended) An enhanced LM609 grafted antibody exhibiting selective binding affinity to $\alpha_v\beta_3$, or a functional fragment thereof, comprising the V_H CDR1 referenced as SEQ ID NO:34; the V_H CDR2 referenced as SEQ ID NO:102; the V_H CDR3 referenced as SEQ ID NO:106; the V_L CDR1 referenced as SEQ ID NO:110; the V_L CDR2 referenced as SEQ ID NO:112; and the V_L CDR3 referenced as SEQ ID NO:90, said grafted antibody or functional fragment thereof having integrin $\alpha_v\beta_3$ binding activity, integrin $\alpha_v\beta_3$ binding specificity or integrin $\alpha_v\beta_3$ -inhibitory activity, wherein LM609 refers to the murine antibody having the heavy chain variable region amino acid sequence referenced as SEQ ID NO:6 and the light chain variable region amino acid sequence referenced as SEQ ID NO:8.

9. (Amended) An enhanced LM609 grafted antibody having substantially the same sequence as [the] an enhanced LM609

Inventors: Huse and Wu
Serial No.: 09/339,922
Filed: June 24, 1999

grafted antibody [of claim 7], or a functional fragment thereof, comprising the V_H CDR1 referenced as SEQ ID NO:34; the V_H CDR2 referenced as SEQ ID NO:102; the V_H CDR3 referenced as SEQ ID NO:106; the V_L CDR1 referenced as SEQ ID NO:110; the V_L CDR2 referenced as SEQ ID NO:112; and the V_L CDR3 referenced as SEQ ID NO:90, said grafted antibody or functional fragment thereof having integrin $\alpha_v\beta_3$ binding activity, integrin $\alpha_v\beta_3$ binding specificity or integrin $\alpha_v\beta_3$ -inhibitory activity, wherein LM609 refers to the murine antibody having the heavy chain variable region amino acid sequence referenced as SEQ ID NO:6 and the light chain variable region amino acid sequence referenced as SEQ ID NO:8.

10. (Amended) An enhanced LM609 grafted antibody exhibiting selective binding affinity to $\alpha_v\beta_3$, or a functional fragment thereof, comprising the V_H CDR1 referenced as SEQ ID NO:34; the V_H CDR2 referenced as SEQ ID NO:104; the V_H CDR3 referenced as SEQ ID NO:106; the V_L CDR1 referenced as SEQ ID NO:110; the V_L CDR2 referenced as SEQ ID NO:112; and the V_L CDR3 referenced as SEQ ID NO:90, said grafted antibody or functional fragment thereof having integrin $\alpha_v\beta_3$ binding activity, integrin $\alpha_v\beta_3$ binding specificity or integrin $\alpha_v\beta_3$ -inhibitory activity, wherein LM609 refers to the murine antibody having the heavy chain variable region amino acid sequence referenced as SEQ ID NO:6 and the light chain variable region amino acid sequence referenced as SEQ ID NO:8.

Inventors: Huse and Wu
Serial No.: 09/339,922
Filed: June 24, 1999

12. (Amended) An enhanced LM609 grafted antibody having substantially the same sequence as [the] an enhanced LM609 grafted antibody [of claim 10], or a functional fragment thereof, comprising the V_H CDR1 referenced as SEQ ID NO:34; the V_H CDR2 referenced as SEQ ID NO:104; the V_H CDR3 referenced as SEQ ID NO:106; the V_L CDR1 referenced as SEQ ID NO:110; the V_L CDR2 referenced as SEQ ID NO:112; and the V_L CDR3 referenced as SEQ ID NO:90, said grafted antibody or functional fragment thereof having integrin $\alpha_v\beta_3$ binding activity, integrin $\alpha_v\beta_3$ binding specificity or integrin $\alpha_v\beta_3$ -inhibitory activity, wherein LM609 refers to the murine antibody having the heavy chain variable region amino acid sequence referenced as SEQ ID NO:6 and the light chain variable region amino acid sequence referenced as SEQ ID NO:8.

25. (Amended) An antibody, or a functional fragment thereof, comprising a CDR selected from the group consisting of a V_H CDR2 referenced as SEQ ID NO:104; a V_H CDR3 referenced as SEQ ID NO:106; and a V_L CDR1 referenced as SEQ ID NO:110, said antibody or functional fragment thereof having integrin $\alpha_v\beta_3$ binding activity, integrin $\alpha_v\beta_3$ binding specificity or integrin $\alpha_v\beta_3$ -inhibitory activity and exhibiting enhanced binding affinity to $\alpha_v\beta_3$ compared to LM609, wherein LM609 refers to the murine antibody having the heavy chain variable region amino acid sequence referenced as SEQ ID NO:6 and the light chain variable region amino acid sequence referenced as SEQ ID NO:8.

Inventors: Huse and Wu
Serial No.: 09/339,922
Filed: June 24, 1999

27. (Amended) An antibody, or functional fragment thereof, comprising the V_H CDR1 referenced as SEQ ID NO:34; a V_H CDR2 referenced as SEQ ID NO:102; a V_H CDR3 referenced as SEQ ID NO:106; a V_L CDR1 referenced as SEQ ID NO:108; a V_L CDR2 referenced as SEQ ID NO:112; and a V_L CDR3 referenced as SEQ ID NO:90, said antibody or functional fragment thereof having integrin $\alpha_v\beta_3$ binding activity, integrin $\alpha_v\beta_3$ binding specificity or integrin $\alpha_v\beta_3$ -inhibitory activity and exhibiting enhanced binding activity to $\alpha_v\beta_3$ compared to LM609, wherein LM609 refers to the murine antibody having the heavy chain variable region amino acid sequence referenced as SEQ ID NO:6 and the light chain variable region amino acid sequence referenced as SEQ ID NO:8.

29. (Amended) An antibody, or a functional fragment thereof, comprising a V_H CDR1 referenced as SEQ ID NO:34; a V_H CDR2 referenced as SEQ ID NO:102; a V_H CDR3 referenced as SEQ ID NO:106; a V_L CDR1 referenced as SEQ ID NO:110; a V_L CDR2 referenced as SEQ ID NO:112; and a V_L CDR3 referenced as SEQ ID NO:90, said antibody or functional fragment thereof having integrin $\alpha_v\beta_3$ binding activity, integrin $\alpha_v\beta_3$ binding specificity or integrin $\alpha_v\beta_3$ -inhibitory activity and exhibiting enhanced binding activity to $\alpha_v\beta_3$ compared to LM609, wherein LM609 refers to the murine antibody having the heavy chain variable region amino acid sequence referenced as SEQ ID NO:6 and the light chain variable region amino acid sequence referenced as SEQ ID NO:8.

Inventors: Huse and Wu
Serial No.: 09/339,922
Filed: June 24, 1999

30. (Amended) The [enhanced LM609 grafted] antibody of claim 29, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)₂ and scFV.

31. (Amended) An antibody, or a functional fragment thereof, comprising a V_H CDR1 referenced as SEQ ID NO:34; a V_H CDR2 referenced as SEQ ID NO:104; a V_H CDR3 referenced as SEQ ID NO:106; a V_L CDR1 referenced as SEQ ID NO:110; a V_L CDR2 referenced as SEQ ID NO:112; and a V_L CDR3 referenced as SEQ ID NO:90, said antibody or functional fragment thereof having integrin $\alpha_v\beta_3$ binding activity, integrin $\alpha_v\beta_3$ binding specificity or integrin $\alpha_v\beta_3$ -inhibitory activity and exhibiting enhanced binding activity to $\alpha_v\beta_3$ compared to LM609, wherein LM609 refers to the murine antibody having the heavy chain variable region amino acid sequence referenced as SEQ ID NO:6 and the light chain variable region amino acid sequence referenced as SEQ ID NO:8.

32. (Amended) The [enhanced LM609 grafted] antibody of claim 30, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)₂ and scFV.

33. (Amended) A nucleic acid molecule having a nucleotide sequence selected from the group of nucleotide sequences consisting of [SEQ ID NO:33, SEQ ID NO:89,] SEQ ID NO:101; SEQ ID NO:103, SEQ ID NO:105, SEQ ID NO:107, SEQ ID NO:109, and SEQ ID NO:111.